| |
著者: Nobuo Shinohara, Toru Harabayashi, Shin Suzuki, Kazuhiro Nagao, Haruo Seki, Masashi Murakumo, Kimiyoshi Mitsuhashi, Takayoshi Demura, Satoshi Nagamori, Hideyasu Matsuyama, Katsusuke Naito, Katsuya Nonomura
雑誌名: Cancer Chemother Pharmacol. 2006 Sep;58(3):402-7. doi: 10.1007/s00280-005-0175-4. Epub 2006 Jan 17.
Abstract/Text
BACKGROUND AND AIMS: The aim of the present phase II study was to evaluate the efficacy of combination chemotherapy of paclitaxel, ifosfamide, and nedaplatin (PIN regimen) in patients with recurrent urothelial cancer who had been treated with cisplatin-based chemotherapy.
PATIENTS/METHODS: Eligible patients were those with histologically confirmed urothelial cancer who had progressed or relapsed after cisplatin-based chemotherapy. The PIN regimen consisted of paclitaxel 175 mg/m(2) on day 1; ifosfamide 4.5 g/m2 divided over days 1, 2, and 3; and nedaplatin 70 mg/m(2) on day 1; PIN was given every 28 days.
RESULTS: Among the 32 patients enrolled in the study (median age, 66 years), complete and partial responses were obtained in 5 patients and 19 patients, respectively, with an overall response rate of 75% (95% confidence interval [CI], 59-91%). The median time to progression was 8 months (range, 0-50+ months) and the median survival was 22 months (range, 4-52+ months). The 1- and 2-year overall survival rates were 53.7 and 42.9%, respectively. All patients experienced Grade 3 or 4 neutropenia, while Grade 3 or 4 thrombocytopenia was seen in 8 patients; Grade 3 or 4 anemia was seen in 6 patients; Grade 3 neuropathy was observed in 1 patient, for whom the PIN therapy was discontinued. There were no treatment-related deaths.
CONCLUSION: The PIN combination was highly active and tolerable in previously treated patients with urothelial cancer as a second-line treatment.
PMID 16416335 Cancer Chemother Pharmacol. 2006 Sep;58(3):402-7. doi: 10.1007/s00280-005-0175-4. Epub 2006 Jan 17.
|
